Indication
Bi-phenotypic leukemia
1 clinical trial
3 products
Clinical trial
A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated LeukemiasStatus: Not yet recruiting, Estimated PCD: 2027-12-31
Product
VenetoclaxProduct
DasatinibProduct
Hyper-CVAD